Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Receivables (2016 - 2025)

Fortress Biotech (FBIO) has 10 years of Change in Receivables data on record, last reported at $2.4 million in Q3 2025.

  • For Q3 2025, Change in Receivables rose 175.37% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $6.8 million, up 98.23%, while the annual FY2024 figure was -$4.5 million, 64.35% up from the prior year.
  • Change in Receivables reached $2.4 million in Q3 2025 per FBIO's latest filing, up from -$2.8 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $8.0 million in Q1 2022 and bottomed at -$10.4 million in Q2 2023.
  • Average Change in Receivables over 5 years is -$254315.8, with a median of -$51000.0 recorded in 2022.
  • The widest YoY moves for Change in Receivables: up 14170.59% in 2023, down 10538.55% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$8.5 million in 2021, then surged by 99.4% to -$51000.0 in 2022, then soared by 14170.59% to $7.2 million in 2023, then crashed by 110.41% to -$747000.0 in 2024, then surged by 423.29% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $2.4 million in Q3 2025, -$2.8 million in Q2 2025, and $8.0 million in Q1 2025.